10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
PFIZER INC | |||
Ticker: PFE Fiscal Year: 2021 | |||
Consolidated Statements of Income | |||
Period Ending Dec 31, 2021 10-K (Filed: Feb 24, 2022) | |||
| (In Millions) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
| Revenues | $ 81,288 | 41,651 | 40,905 |
| Costs and expenses: | |||
| Cost of sales | 30,821 | 8,484 [1] | 8,054 |
| Selling, informational and administrative expenses | 12,703 | 11,597 | 12,726 |
| Research and development expenses | 13,829 | 9,393 | 8,385 |
| Amortization of intangible assets | 3,700 | 3,348 | 4,429 |
| Restructuring charges and certain acquisition-related costs | 802 | 579 | 601 |
| (Gain) on completion of Consumer Healthcare JV transaction | 0 | (6) | (8,107) |
| Other (income)/deductionsnet | (4,878) | 1,219 | 3,497 |
| Income from continuing operations before provision/(benefit) for taxes on income | 24,311 | 7,036 | 11,321 |
| Provision/(benefit) for taxes on income | 1,852 | 370 | 583 |
| Income from continuing operations | 22,459 | 6,666 | 10,738 |
| Discontinued operationsnet of tax | (434) | 2,529 | 5,318 |
| Net income before allocation to noncontrolling interests | 22,025 | 9,195 | 16,056 |
| Less: Net income attributable to noncontrolling interests | 45 | 36 | 29 |
| Net income attributable to Pfizer Inc. common shareholders | 21,979 | 9,159 | 16,026 |
| Earnings per common sharebasic: | |||
| Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) | 4.00 | 1.19 | 1.92 |
| Discontinued operationsnet of tax (in dollars per share) | (0.08) | 0.46 | 0.95 |
| Net income attributable to Pfizer Inc. common shareholders (in dollars per share) | 3.92 | 1.65 | 2.88 |
| Earnings per common sharediluted: | |||
| Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) | 3.93 | 1.18 | 1.89 |
| Discontinued operationsnet of tax (in dollars per share) | (0.08) | 0.45 | 0.94 |
| Net income attributable to Pfizer Inc. common shareholders (in dollars per share) | 3.85 | 1.63 | 2.82 |
| Weighted-average sharesbasic | 5,601 | 5,555 | 5,569 |
| Weighted-average sharesdiluted | 5,708 | 5,632 | 5,675 |
| [1] Exclusive of amortization of intangible assets, except as disclosed in Note 1M. | |||
| External Links | |
| PFIZER INC (PFE) Fiscal Year 2021 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |